Zevra Homepage.
icon news News
icon investors
Investors
  • Overview
  • Events & Presentations
  • Stock Information
  • - Stock Quote & Chart
  • - Historic Stock Lookup
  • - Analyst Coverage
  • Press Releases
  • Corporate Governance
  • - Committee Composition
  • - IRS – Required Disclosures
  • State Compliance
  • SEC Filings
  • Email Alerts
  • FAQs
icon careers Careers icon contact Contacts
  • About Us dropdown arrow dropdown arrow mobile
    • Our Mission & Vision
    • The Zevra Story
    • Leadership
    • Board of Directors
    • What We Do
    • Partnering
  • Patients & Caregivers dropdown arrow dropdown arrow mobile
    • Clinical Trials
    • Expanded Access Policy
    • Niemann-Pick Disease Type C
    • Urea Cycle Disorders
    • Vascular Ehlers-Danlos
    • Sleep Disorders
  • Our Products
    • MIPLYFFA®
    • OLPRUVA®
    • AZSTARYS®
  • Our Pipeline dropdown arrow dropdown arrow mobile
    • Pipeline
    • Clinical Trials
    • Publications & Presentations
    • Medical Literature
    • Medical Information
    • Investigator-Initiated Studies
  • News
  • Investors dropdown arrow dropdown arrow mobile
    • Overview
    • Events & Presentations
    • Stock Information
    • - Stock Quote & Chart
    • - Historic Stock Lookup
    • - Analyst Coverage
    • Press Releases
    • Corporate Governance
    • - Committee Composition
    • - IRS – Required Disclosures
    • State Compliance
    • SEC Filings
    • Email Alerts
    • FAQs
  • Careers
  • Contacts

Home >

Arimoclomol in adults with NPC in a real-world setting: Long-term data from an expanded access program in the USA

April 15, 2024

Evaluation of the Long-Term Effect of Arimoclomol in NPC – 48 Months Data from CT-ORZY-NPC-002

October 4, 2023

Real World Data Collection in Niemann-Pick Disease Type C – Data from Expanded Access Program with Arimoclomol

Cardiovascular (CV) Safety and Pharmacokinetics (PK) of Serdexmethylphenidate (SDX), a Prodrug of d-Methylphenidate (d-MPH) Compared to Ritalin and Ritalin LA in a Single-Dose Crossover Study in Healthy Volunteers

September 8, 2023

Serdexmethylphenidate/dexmethylphenidate effects on sleep in children with attention-deficit/hyperactivity disorder

July 3, 2023

A Clinical Study with KP1077 in Adults with Idiopathic Hypersomnia

June 7, 2023

Validation of the 5-domain Niemann-Pick type C Clinical Severity Scale

April 4, 2023

Clinical disease progression and biomarkers in Niemann–Pick disease type C: a prospective cohort study

Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment

March 1, 2023

Association Between NPC Severity Score Domains and Corresponding Items of the Performance-based Scale for the Assessment and Rating of Ataxia (SARA)

February 23, 2023

Posts pagination

Previous 1 … 4 5 6 … 8 Next
About Us
Our Mission & Vision The Zevra Story Leadership Board of Directors What We Do Partnering
Patients & Caregiver
Clinical Trials Expanded Access Policy Niemann-Pick Disease Type C Urea Cycle Disorders Vascular Ehlers-Danlos Sleep Disorders
Our Products
MIPLYFFA® OLPRUVA® AZSTARYS®
Our Pipeline
Pipeline Clinical Trials Publications & Presentations Medical Literature Medical Information Investigator-Initiated Studies
Careers
Culture Job Openings
Investors
Investor Relations Events & Presentations Stock Quote & Chart Press Releases Corporate Governance SEC Filings Contact Email Alerts
Contact [email protected] 888.958.1253
Zevra Logo
Footer link Zevra Facebook
Footer link Zevra X twitter
Footer link Zevra linkedin
© 2026 Zevra Therapeutics.
All rights reserved.
|
Privacy Policy
|
Notice at Collection
|
Your Privacy Choices
|
Terms of Use